Angiorus

Angiorus is a venotonic and venoprotective pharmaceutical product developed by Novosibkhimpharm (a subsidiary of Binnopharm Group) for the treatment of chronic venous diseases and hemorrhoids. It consists of a micronized purified flavonoid fraction (MPFF) containing 900 mg of diosmin and 100 mg of hesperidin. The micronization process significantly increases the surface area of the drug particles, enhancing gastrointestinal absorption and clinical efficacy compared to non-micronized forms. Angiorus works by increasing venous tone through the inhibition of catechol-O-methyltransferase (COMT), which leads to prolonged norepinephrine activity on the venous wall. Additionally, it exerts anti-inflammatory effects by inhibiting the synthesis of prostaglandins and leukotrienes, thereby reducing capillary permeability and improving lymphatic drainage. It is approved in Russia for the symptomatic relief of leg pain, heaviness, and swelling associated with venous-lymphatic insufficiency, as well as for the management of acute and chronic hemorrhoidal episodes.

Brand names

AngiorusАНГИОРУС

Other names

diosmin + hesperidinMicronized purified flavonoid fractionMPFF